Voretigene Neparvovec-Rzyl

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 171 publications

Microperimetry is a valuable tool for assessing changes in visual function following voretigene neparvovec-rzyl gene therapy.

Microperimetry is a valuable tool for assessing changes in visual function following voretigene neparvovec-rzyl gene therapy.

Journal: Ophthalmic genetics
Published: June 16, 2026

Clinical experience with gene therapy for autosomal recessive RPE65-related retinal dystrophy in the Arabian Gulf.

Clinical experience with gene therapy for autosomal recessive RPE65-related retinal dystrophy in the Arabian Gulf.

Journal: Ophthalmology. Retina
Published: May 02, 2026

Adeno-Associated Virus Gene Delivery to Hard-to-Transduce Tissues: Biological Barriers, Engineering Strategies, and Clinical Challenges.

Adeno-Associated Virus Gene Delivery to Hard-to-Transduce Tissues: Biological Barriers, Engineering Strategies, and Clinical Challenges.

Journal: Human gene therapy
Published: April 04, 2026

A heterozygous pathogenic RPE65 variant phenocopies a mitochondrial retinopathy.

A heterozygous pathogenic RPE65 variant phenocopies a mitochondrial retinopathy.

Journal: Ophthalmic genetics
Published: March 18, 2026

Four-Year Structural and Functional Outcomes of the First Subretinal Voretigene Neparvovec-rzyl Treatment for RPE65-Associated Inherited Retinal Dystrophy in Korea.

Four-Year Structural and Functional Outcomes of the First Subretinal Voretigene Neparvovec-rzyl Treatment for RPE65-Associated Inherited Retinal Dystrophy in Korea.

Journal: Korean journal of ophthalmology : KJO
Published: January 19, 2026

Vision Outcomes in Children Treated With Voretigene Neparvovec for RPE65-Associated Retinopathy.

Vision Outcomes in Children Treated With Voretigene Neparvovec for RPE65-Associated Retinopathy.

Journal: JAMA ophthalmology
Published: January 02, 2026

Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation.

Gene-Agnostic Therapeutic Strategies for Inherited Retinal Diseases: Neuroprotection and Immunomodulation.

Journal: Genes
Published: January 01, 2026

Clinical and pharmacovigilance safety evaluation of LUXTURNA® (voretigene neparvovec-rzyl).

Clinical and pharmacovigilance safety evaluation of LUXTURNA® (voretigene neparvovec-rzyl).

Journal: Cutaneous and ocular toxicology
Published: October 27, 2025

Gene Therapy for Inherited Retinal Disease: Current Strategies, Personalized Medicine, and Future Implications-A Comprehensive Review.

Gene Therapy for Inherited Retinal Disease: Current Strategies, Personalized Medicine, and Future Implications-A Comprehensive Review.

Journal: Journal of personalized medicine
Published: October 20, 2025

Mechanisms and Functions of Chromophore Regeneration in the Classical Visual Cycle: Implications for Retinal Disease Pathogenesis and Therapy.

Mechanisms and Functions of Chromophore Regeneration in the Classical Visual Cycle: Implications for Retinal Disease Pathogenesis and Therapy.

Journal: Biomolecules
Published: October 17, 2025

Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease.

Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease.

Journal: Advanced drug delivery reviews
Published: October 12, 2025

One down but many more to go: the state of gene therapy for inherited retinal disease.

One down but many more to go: the state of gene therapy for inherited retinal disease.

Journal: Regenerative medicine
Published: October 07, 2025
Showing 1-12 of 171

Last Updated: 06/30/2026